1.1Antibody tether for the tag
An antibody fragment fused to a peptide tag binds an extracellular domain of a tumor surface protein. The exposed peptide tag provides a binding site for the receptor on the administered immune cells.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
An antibody fragment fused to a peptide tag binds an extracellular domain of a tumor surface protein. The exposed peptide tag provides a binding site for the receptor on the administered immune cells.
A chemically stabilized aptamer binds an extracellular domain of a tumor surface protein. A spacer holds the attached peptide tag away from the bound aptamer so the immune cell receptor can engage it.
Tumor cells internalize and process the supplied protein antigen and display a derived peptide on a compatible class I major histocompatibility molecule. Engineered T cells recognize the resulting peptide–molecule complex through their T cell receptor and release cytotoxic granules.
An antibody binds the exposed tag through its antigen-binding arms and engages the native Fc receptor CD16 on the administered natural killer cells. Receptor clustering triggers release of cytotoxic granules toward the antibody-coated cell.
The adapter has an antigen-binding arm and a separate peptide that serves as the CAR binding site. The arm captures displayed antigen on the tumor cell, and the peptide recruits the CAR-expressing immune cell.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A two-chain antigen-binding fragment replaces the single-chain variable fragment in the chimeric receptor. The fragment's heavy-chain portion connects to the receptor hinge and membrane anchor, while the separately expressed light chain pairs with it at the cell surface. The assembled binding site recognizes the synthetic peptide displayed on sortase-tagged target cells.
Three populations of model target cells carry low, intermediate, and high surface densities of the same synthetic antigen. Calibrated fluorescence measurements identify populations whose median tag densities have an approximate ratio of 1 to 3 to 10. Each population is combined with receptor-bearing cells at a 1 to 1 cell ratio. A common assay endpoint measures how reporter activation varies with tag density.
A microfluidic culture chip holds a tumor spheroid in a chamber adjacent to a perfusion channel. Sortase and the synthetic antigen conjugate enter through the channel, and a wash removes unbound conjugate before receptor-bearing cells enter through the same channel. Time-lapse microscopy records receptor-bearing cell entry into the spheroid and changes in tumor cell viability.
A porous membrane insert divides a culture well into compartments that share soluble medium while retaining cells. Sortase-tagged target cells occupy the lower compartment, and receptor-bearing immune cells occupy the insert. A paired well places both cell populations in direct contact. Target viability in both wells and soluble signaling markers in the shared medium provide readouts of contact-dependent activity.
An automated microscope measures surface tag fluorescence in wells containing sortase-treated tumor cultures and in paired untagged control wells. Software segments the target cells and calculates the fraction with fluorescence above a threshold derived from the controls. A liquid handler adds a fixed number of receptor-bearing cells when the tagged fraction reaches a preset acceptance value. The system records the measured fraction and dispensing time for each well.
A hydrophilic spacer connects the recognition tag to a phospholipid anchor. After local delivery into an accessible tumor, the lipid tails insert into cell membranes and the spacer presents the tag to immune cells.
A recombinant tag protein carries a C-terminal LPETG sequence downstream of its recognition epitope. Sortase cleaves between the threonine and glycine and transfers the tag protein to a surface acceptor with an exposed N-terminal oligoglycine.
A tumor-binding antibody fragment carries an exposed N-terminal triglycine acceptor. The fragment binds a tumor surface protein, where sortase couples the recognition tag to the acceptor.
A single-chain antibody fragment recognizes the displayed peptide tag. A flexible linker joins the antibody variable domains, and a hinge connects the fragment to the CAR transmembrane segment.
Primary T cells express a tag-binding receptor with intracellular 4-1BB and CD3 zeta signaling domains. Engagement with the surface tag clusters the receptor and activates T cell signaling and cytotoxic granule release.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The cytotoxicity of Srt.bbz and Srt.28z was compared in a cell killing assay using Her2+SKOV3 cells that were incubated with Her2-scFv and then washed to remove excess scFv (i.e. preloaded). The SIR-T cells were then added at two different E:T ratios, which demonstrated a higher percent lysis of the SKOV3 cells by the Srt.bbz cells versus the Srt.28z (FIG. 8B).B · US 2021/0347845 A1 · ¶ 243
As a result of introducing CD19-specific CAR genes into T cells collected from the patients, culturing and proliferating the cells, and infusing them into the patients' bodies, molecular biological remission in the bone marrow was obtained in all 5 cases (see, for example, NPL 2).A · US 2019/0343880 A1 · ¶ 3
In one aspect, the method comprises administering to a subject in need thereof a therapeutically effective amount of a composition comprising an engineered T cell comprising a sortase CAR.B · US 2021/0347845 A1 · ¶ 175
An empty cell means only that no passage was reproduced there.
In particular, the present invention relates to a chimeric antigen receptor gene-modified lymphocyte capable of exerting a cytocidal effect on a highly EPHB4 receptor (Ephrin type-B receptor 4) expressing tumor, use thereof, and the like.A · US 2019/0343880 A1 · ¶ 1
This process has been utilized by research groups to incorporate site-specific moieties and functional groups on the cell surface of eukaryotic cells in ways that cannot be produced by genetically modifying the cell.B · US 2021/0347845 A1 · ¶ 2
Multiple moieties can be attached to a cell surface in predefined proportions based on their stoichiometry.B · US 2021/0347845 A1 · ¶ 2
patent.fyi, US 2026/0355317 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355317/, SHA-256 ede52610d667ad656d1684073098ca8b56690140766c30025caf4129abd6cd72